The Law Offices of Frank R. Cruz Announces Investigation of BioXcel Therapeutics, Inc. (BTAI) on Behalf of InvestorsBusiness Wire • 06/29/23
BioXcel CEO Vimal Mehta Says This Alzheimer's News Is A 'Huge Win For Society'Investors Business Daily • 06/29/23
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer's Disease-Related AgitationGlobeNewsWire • 06/29/23
BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 WillSeeking Alpha • 05/29/23
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less CertainInvestors Business Daily • 05/25/23
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or SchizophreniaGlobeNewsWire • 05/25/23
BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) ProgramGlobeNewsWire • 05/16/23
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational HighlightsGlobeNewsWire • 05/08/23
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEOInvestors Business Daily • 05/04/23
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care ConferenceGlobeNewsWire • 05/02/23
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023GlobeNewsWire • 04/24/23
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public OfferingGlobeNewsWire • 03/14/23